TABLE 2.
Main clinical characteristics associated with patient death and acute respiratory disease distress syndrome
| Mortality | ARDS | |||||
|---|---|---|---|---|---|---|
| Alive (n = 76) | Death (n = 28) | P-value | No (n = 47) | ARDS (n = 57) | P-value | |
| Clinical characteristics | ||||||
| Age (y, mean ± SD) | 55 ± 11.4 | 70.8 ± 9.4 | <.001 | 57.8 ± 12.4 | 61.3 ± 13.2 | .16 |
| Sex (n, %): female/male | 31/45 (40.8/59.2) | 13/15 (46.4/53.6) | .60 | 21/26 (40.7/55.3) | 23/34 (40.4/59.6) | .65 |
| Race (n, %): Caucasian/other | 64/12 (84.2/15.8) | 27/1 (96.4/3.6) | .17 | 40/7 (85.1/14.9) | 51/6 (89.5/ 10.5) | .5 |
| Comorbidities (n, %) | ||||||
| Hypertension (n) (no/ACEI/ARB/other) | 10/6/21/38 (13/8/28/50) | 4/2/8/14 (14/7/28/50) | .98 | 7/5/14/20 (15/10/30.4/43.5) | 7/3/15/32 (12.3/5.3/23.3/56.1) | .51 |
| Diabetes | 21 (27) | 11 (39) | .25 | 12 (25.5) | 20 (35.1) | .29 |
| Obesity | 17 (22.4) | 11 (39.3) | .08 | 8 (17) | 20 (35.1) | .03 |
| Cardiac disease | 20 (19.4) | 11 (39.3) | .2 | 16 (34.8) | 15 (26.3) | .35 |
| Pulmonary disease | 6 (7.9) | 10 (35.7) | <.001 | 5 (10.6) | 11 (19.3) | .28 |
| Active cancer | 3 (3.9) | 5(17.9) | .03 | 3 (6.4) | 5 (8.8) | .64 |
| Lymphopenia before admission | 31 (41.3) | 14 (50) | .43 | 22 (47.8) | 23 (44.4) | .44 |
| Days from symptoms onset to admission (median, IQR)a | 7 (3-10) | 6 (4-10) | .76 | 7 (3-10) | 6 (4-10.7) | .77 |
| Initial symptoms (n, %) | ||||||
| Fever | 60 (78.9) | 21 (75) | .66 | 39 (83.1) | 42 (73.7) | .3 |
| Cough | 52 (68.4) | 19 (67.9) | .95 | 30 (63.8) | 41 (71.9) | .29 |
| Dyspnea | 21 (27.6) | 17 (60.7) | .002 | 9 (19) | 29 (50.9) | <.001 |
| Myalgia | 25 (32.9) | 9 (31.1) | .94 | 14 (29.8) | 20 (35.1) | .56 |
| Diarrhea | 22 (28.9) | 10 (35.7) | .50 | 12 (25.5) | 20 (35.1) | .29 |
| Nosocomial COVID-19 infection (n, %) | 6 (7.9) | 8 (28.6) | .01 | 6 (12.8) | 9 (15.8) | .66 |
| Initial Spo2 (%, mean ± SD) | 96.4 ± 2.4 | 94.8 ± 3.6 | .12 | 96.6 ± 2.2 | 95.3 ± 3.3 | .03 |
| Initial Spo2/Fio2 (mean ± SD) | 407.3 ± 97.3 | 353.2 ± 123.4 | .03 | 432.1 ± 76.6 | 357.4 ± 118.5 | .001 |
| Any radiography infiltrate initially (n, %) | 53 (69.7) | 23 (82.1) | .23 | 33 (70.2) | 43 (75.4) | .55 |
| Transplant characteristics | ||||||
| Type of transplant (n, %) | ||||||
| First kidney transplant | 65 (85.5) | 23 (82.1) | .76 | 41 (87.2) | 47 (82.5) | .50 |
| Type of donor (n, %) | ||||||
| Cadaveric | 62 (81.6) | 28 (100) | .01 | 37 (78.7) | 53 (93) | .04 |
| ECD | 22 (37.9) | 16 (66.7) | .02 | 13 (35.1) | 25 (55.6) | .06 |
| Induction therapy (n, %) | ||||||
| None | 8 (10.5) | 3 (10.7) | .88 | 4 (8.5) | 7 (12.3) | .73 |
| rATG | 26 (34.2) | 11 (39.3) | 16 (34) | 21 (36.8) | ||
| Basiliximab | 42 (55.3) | 14 (50) | 27 (57.4) | 29 (50.9) | ||
| Maintenance therapy (n, %) | ||||||
| TAC use | 66 (86.8) | 23 (82.1) | .54 | 40 (85.1) | 49 (86) | .9 |
| mTORi use | 22 (21.6) | 4 (3.9) | .19 | 15 (31.9) | 11 (20) | .1 |
| MMF/MPA use | 61 (80.3) | 26 (92.9) | .14 | 38 (80.9) | 49 (86) | .48 |
| Prednisone use | 71 (93.4) | 24 (85.7) | .21 | 44 (93.6) | 51 (89.5) | .4 |
| Time after transplant | ||||||
| <6 mo (n, %) | 6 (11.8) | 6 (21.4) | .21 | 5 (10.6) | 10 (17.5) | .40 |
| Time (mo, median, IQR) | 56.5 (20-130.5) | 71.6 (6-135) | .8 | 65 (24-133) | 57 (12.5-127) | .33 |
Abbreviations: ARDS, acute respiratory distress syndrome; CI, confidence interval; Fio2, fraction of inspired oxygen; MMF/MPA, mycophenolate mofetil or mycophenolic acid; mTORi, mammalian target of rapamycin inhibitors; rATG, rabbit antithymocyte globulin; SD, standard deviation; Spo2, blood oxygen saturation measured by pulse oximetry; TAC, tacrolimus.
a
Those who were hospitalized because of other reasons were excluded from the analysis.